Last reviewed · How we verify

intravenous sufentanil

Jun Wang · FDA-approved active Small molecule Quality 5/100

intravenous sufentanil is a Small molecule drug developed by Jun Wang. It is currently FDA-approved. Also known as: SI.

At a glance

Generic nameintravenous sufentanil
Also known asSI
SponsorJun Wang
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about intravenous sufentanil

What is intravenous sufentanil?

intravenous sufentanil is a Small molecule drug developed by Jun Wang.

Who makes intravenous sufentanil?

intravenous sufentanil is developed and marketed by Jun Wang (see full Jun Wang pipeline at /company/jun-wang).

Is intravenous sufentanil also known as anything else?

intravenous sufentanil is also known as SI.

What development phase is intravenous sufentanil in?

intravenous sufentanil is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing